Evolus, Inc. (NASDAQ:EOLS) Receives $17.50 Average Target Price from Analysts

Shares of Evolus, Inc. (NASDAQ:EOLS) have been assigned a consensus rating of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $17.50.

EOLS has been the topic of several research analyst reports. BTIG Research reiterated a “buy” rating and issued a $13.00 price objective on shares of Evolus in a report on Wednesday. Stifel Nicolaus cut their price target on shares of Evolus from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Tuesday, January 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd. HC Wainwright dropped their price objective on shares of Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Finally, Mizuho set a $15.00 target price on shares of Evolus in a research note on Wednesday, February 4th.

More Evolus News

Here are the key news stories impacting Evolus this week:

• Positive Sentiment: Company issued FY‑2026 revenue guidance of $327M–$337M, above Street consensus (~$316M), signaling higher growth expectations for 2026 and supporting upside to sales forecasts. Evolus outlines 2026 revenue guidance
• Positive Sentiment: Company reported strong 2025 results (nearly $300M in total net revenue, sixth consecutive year of double‑digit growth) and said it expects sustainable profitability beginning in 2026 — a material shift in the story toward margin improvement. Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results
• Positive Sentiment: BTIG Research reaffirmed a “buy” rating and set a $13 price target — a substantial upside from recent levels that likely encouraged momentum trading and contributed to the rally. BTIG reaffirmed buy (Benzinga)
• Neutral Sentiment: Investors and analysts are parsing call/transcript details on product portfolio expansion and international rollouts; several transcripts and call highlights are available for deeper review. Earnings call highlights (Yahoo)
• Neutral Sentiment: Some outlets reported slightly different EPS metrics (adjusted vs. GAAP), e.g., Zacks noted an EPS in line with its estimate — this creates mixed headline reads but doesn’t change the top‑line/guidance narrative. Zacks: matches Q4 earnings estimates
• Negative Sentiment: There are mixed EPS headlines: some reports showed a miss on the quarterly EPS figure versus consensus (reported $0.00 vs. $0.09 estimate in one summary), which could temper enthusiasm if profitability metrics disappoint. Evolus earnings summary (MarketBeat)
• Negative Sentiment: Analyst models still show an overall negative EPS outlook for the current fiscal year in some consensus tallies, indicating profitability remains a forward risk if execution or margins slip. Earnings call transcript (Seeking Alpha)

Insider Buying and Selling at Evolus

In other news, insider David Moatazedi sold 10,539 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $7.15, for a total value of $75,353.85. Following the sale, the insider directly owned 354,388 shares in the company, valued at approximately $2,533,874.20. This trade represents a 2.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Evolus

Institutional investors have recently modified their holdings of the company. Seven Fleet Capital Management LP purchased a new position in Evolus in the fourth quarter valued at $545,000. Alpine Global Management LLC purchased a new position in shares of Evolus in the 4th quarter valued at $173,000. Virtu Financial LLC acquired a new stake in Evolus during the 4th quarter worth $151,000. Mercer Global Advisors Inc. ADV purchased a new stake in Evolus in the fourth quarter valued at $144,000. Finally, Wellington Management Group LLP lifted its position in Evolus by 5.9% in the fourth quarter. Wellington Management Group LLP now owns 195,160 shares of the company’s stock valued at $1,298,000 after acquiring an additional 10,850 shares during the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.

Evolus Stock Performance

Shares of EOLS stock opened at $5.59 on Monday. The firm has a market cap of $362.34 million, a P/E ratio of -6.90 and a beta of 1.02. The firm’s 50 day moving average price is $5.09 and its 200-day moving average price is $6.24. Evolus has a one year low of $4.09 and a one year high of $14.60.

Evolus (NASDAQ:EOLS) last announced its earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The business had revenue of $90.30 million during the quarter, compared to the consensus estimate of $89.58 million. As a group, research analysts predict that Evolus will post -0.61 EPS for the current fiscal year.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.